BioPharma Resources

Drug Trial Radar · NCT07419295

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator's Choice of Non-platinum Chemotherapy in Participants With Pretreated Locally Advanced/Metastatic Urothelial Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Apr 23, 2026

Primary completion

Jul 27, 2029

Study completion Apr 23, 2030

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and targeted therapy. Researchers want to know if giving sacituzumab tirumotecan (sac-TMT), the trial medicine, can treat locally advanced or metastatic UC that got worse after certain treatments. The goal of this trial is to learn if people who receive sac-TMT live longer than those who receive certain non-platinum chemotherapies.

Conditions

  • Bladder Cancer

Interventions

  • Sacituzumab tirumotecanBiological

    IV infusion

  • VinflunineDrug

    IV infusion

  • DocetaxelDrug

    IV infusion

  • PaclitaxelDrug

    IV infusion

  • Rescue medications for sacituzumab tirumotecanDrug

    Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medications are pegfilgrastim or equivalent, histamine-1 (H1) receptor antagonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent, and steroid mouthwash (dexamethasone or equivalent).

  • Rescue medications for chemotherapyDrug

    Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medications are dexamethasone or equivalent, H1 receptor antagonist, H2 receptor antagonist, and laxative.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to approximately 40 months

Locations

117 sites in 17 countries. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian ( Site 0814)

    Newport Beach, California · Recruiting

  • University Of Colorado Anschutz Medical Campus ( Site 0807)

    Aurora, Colorado · Recruiting

  • University of Colorado Health - Highlands Ranch Hospital ( Site 0847)

    Highlands Ranch, Colorado · Recruiting

  • University of Colorado Health - Lone Tree Medical Center ( Site 0848)

    Lone Tree, Colorado · Recruiting

  • Sibley Memorial Hospital ( Site 0849)

    Washington D.C., District of Columbia · Recruiting

  • Emory University Hospital ( Site 0824)

    Atlanta, Georgia · Recruiting

  • University of Chicago ( Site 0845)

    Chicago, Illinois · Recruiting

  • Johns Hopkins University ( Site 0843)

    Baltimore, Maryland · Recruiting

  • Dana Farber Cancer Institute ( Site 0783)

    Boston, Massachusetts · Recruiting

  • Munson Medical Center ( Site 0812)

    Traverse City, Michigan · Recruiting

  • Morristown Memorial Hospital ( Site 0795)

    Morristown, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center ( Site 0832)

    New York, New York · Recruiting

  • WakeMed Raleigh Campus ( Site 0811)

    Raleigh, North Carolina · Recruiting

  • TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0822)

    Cincinnati, Ohio · Recruiting

  • University Hospitals of Cleveland Case Medical Center ( Site 0834)

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic - Ohio ( Site 0793)

    Cleveland, Ohio · Recruiting

  • Fox Chase Cancer Center ( Site 0830)

    Philadelphia, Pennsylvania · Recruiting

  • The West Clinic, P.C. ( Site 0791)

    Germantown, Tennessee · Recruiting

  • Thompson Cancer Survival Center ( Site 0803)

    Knoxville, Tennessee · Recruiting

  • Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 0831)

    Nashville, Tennessee · Recruiting

  • University of Utah, Huntsman Cancer Institute ( Site 0810)

    Salt Lake City, Utah · Recruiting

  • Virginia Oncology Associates (VOA) ( Site 8002)

    Norfolk, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center ( Site 0787)

    Seattle, Washington · Recruiting

  • Hospital Italiano de Buenos Aires ( Site 0004)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Asociacion de Beneficencia Hospital Sirio Libanes ( Site 0003)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 0002)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto de Oncologia de Rosario ( Site 0005)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Macquarie University ( Site 0031)

    Macquarie, New South Wales, Australia · Recruiting

  • Mater Hospital Brisbane ( Site 0032)

    South Brisbane, Queensland, Australia · Recruiting

  • CHC Montlegia Clinic ( Site 0061)

    Liège, Belgium · Recruiting

  • Cliniques Universitaires Saint-Luc ( Site 0062)

    Brussels, Bruxelles-Capitale, Region de, Belgium · Recruiting

  • AZ Maria Middelares ( Site 0063)

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • UZ Gent ( Site 0064)

    Ghent, Oost-Vlaanderen, Belgium · Recruiting

  • Hospital Alemao Oswaldo Cruz ( Site 0101)

    São Paulo, Brazil · Recruiting

  • ICTRIALS Pesquisa e Desenvolvimento ( Site 0107)

    Curitiba, Paraná, Brazil · Recruiting

  • Hospital Moinhos de Vento ( Site 0102)

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0110)

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Lakeridge Health ( Site 0122)

    Oshawa, Ontario, Canada · Recruiting

  • Princess Margaret Cancer Centre ( Site 0123)

    Toronto, Ontario, Canada · Recruiting

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0121)

    Québec, Quebec, Canada · Recruiting

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.